Search is Powered by Google
Lymphoma / Leukemia News

Survival Of Young Infants With Acute Lymphoblastic Leukaemia Increases With New Treatment Protocol

rate icon Editor's Choice
Main Category: Lymphoma / Leukemia
Also Included In: Pediatrics / Children's Health;  Clinical Trials / Drug Trials;  Cancer / Oncology
Article Date: 20 Jul 2007 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 and a half stars

4.5 (2 votes)

Health Professional:not yet rated

Article Opinions: 1 posts

Infants less than one year old with acute lymphoblastic leukaemia have increased survival with a new treatment protocol, compared to those on conventional regimes, according to a report in this week's medical journal The Lancet.

Acute lymphoblastic leukaemia (ALL) in babies under one year of age is rare and biologically different from ALL in older babies and children. Over the last 40 years the cure rate for ALL has improved from 10% to 80%, but not for infants less than twelve months' old, where current event-free survival (EFS) stands at around 17-45%.

Dr. Rob Pieters, Erasmus MC-Sophia Childrens' Hospital, Rotterdam, Netherlands, and team, carried out a study of 482 infants under one year of age - from 22 different countries. The babies were listed in risk-order following their peripheral blood response to a standard ALL 7-day predisone pre-treatment for ALL. They then received a hybrid treatment regime based on the standard treatment protocol for ALL, which incorporated some elements designed for treatment of AML (acute myeloid leukaemia).

After a three-year follow-up 58% of those who received the hybrid treatment were in complete remission, and at four years 47% had experienced EFS, compared to 17-45% EFS in previous studies of ALL. The researchers also reported that the hybrid treatment protocol did not produce more toxic effects than previous treatments. "Patients treated with our hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL," said the authors.

"We believe that this hybrid treatment protocol will be used as the standard for continuing international collaborative studies that aim to further improve outcomes for acute lymphoblastic leukaemia in infants," the authors concluded.

"New Treatment Protocol Increases Survival Of Very Young Infants With Acute Lymphoblastic Leukaemia"
Dr. Rob Pieters et al
http://www.thelancet.com

Written by: Christian Nordqvist
Editor: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today


Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Lymphoma? Lymphoma Symptoms, Causes and Treatments
15 Apr 2009
Lymphoma is a type of cancer that begins in immune system cells called lymphocytes. Like other cancers, lymphoma occurs when lymphocytes are in a state of uncontrolled cell growth and multiplication...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating Lymphoma Early image Treating Lymphoma Early

Non-Hodgkin's lymphoma is a cancer of the immune system. First-line treatment options include radiation therapy, chemotherapy, immunotherapy, radioimmunotherapy and stem cell transplant. How do you figure out which is right for you...

View more videos...